Summary

• I started writing/researching Bausch Health after its implosion in 2018.
• Since then I've written 25 articles about Bausch Health.
• I've created an index to be able to quickly reference my notes as I'm working on an update.
• New note coming soon.

This is an overview of my articles on Bausch Health (BHC). I started analyzing it in November 2018 after it imploded in a scandal related to fraud and universally hated. The company is basically down from where it was when I first wrote it up over two years ago. 

Data by YCharts

I've put together this index as much for myself as for you. I'm currently looking at the company again. So I can more quickly reference past write-ups. From oldest to newest:

Valeant Pharmaceuticals - Buying The Uninvestable (NYSE:BHC)

Valeant: I Hate To Say It But I Believe +16% Was Overdone (NYSE:BHC)

Valeant Can Go Bankrupt (NYSE:BHC)

Valeant Or Deutsche Bank? (NYSE:BHC)

Valeant: The Effect Of A Salix Sale On Its Bottom Line (NYSE:BHC)

Is Valeant Lighting Dollar Bills On Fire With Its Salix Sale? (NYSE:BHC)

Valeant: On The Road To 4x Debt/EBITDA (NYSE:BHC)

Valeant: Change Is Good (NYSE:BHC)

Objective Review Of Valeant's Asset Sales (NYSE:BHC)

Valeant - It's Not About This Quarter Or The Next Quarter (NYSE:BHC)

Valeant - It's Not About This Quarter Or The Next Quarter (NYSE:BHC)

Valeant: Chipping Away, Billion By Billion (NYSE:BHC)

It Ain't Over Until It's Over (NYSE:BHC)

Ackman: Buy At $200, Sell At $11 (NYSE:BHC)

Name Change: Signal Decoded (NYSE:BHC)

Valeant's Story Is Changing (NYSE:BHC)

4 Arguments Against The Valeant Bear Case (NYSE:BHC)

Why This Valeant Bull Doesn't Like The INova Deal (NYSE:BHC)

Valeant: Why JPMorgan Is Asking Fundamentally The Wrong Question (NYSE:BHC)

The Good And Bad About The Obagi Sale (NYSE:BHC)

Valeant: There's No Denying It (NYSE:BHC)

Valeant: A Humble But Crafty Deal (NYSE:BHC)

Update: Valeant's Turnaround Progressing To Midgame (NYSE:BHC)

Valeant: Endgame (NYSE:BHC)

Bausch Health Companies: Careful For Now (NYSE:BHC)